Home » Stocks » SLNO

Soleno Therapeutics, Inc. (SLNO)

Stock Price: $2.11 USD 0.05 (2.43%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $2.13 +0.02 (0.95%) Jan 22, 5:22 PM
Market Cap 164.01M
Revenue (ttm) n/a
Net Income (ttm) -36.41M
Shares Out 79.58M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $2.11
Previous Close $2.06
Change ($) 0.05
Change (%) 2.43%
Day's Open 2.06
Day's Range 2.03 - 2.13
Day's Volume 294,676
52-Week Range 1.61 - 4.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 weeks ago

Soleno Therapeutics is currently developing Diazoxide Choline Controlled-Release tablets and has a distinctive advantage in how well-documented the safety profile of DCCR's parent molecule, Di...

GlobeNewsWire - 2 weeks ago

REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

GlobeNewsWire - 1 month ago

Soleno intends to submit plans to FDA to conduct further analyses of clinical data from completed and ongoing studies of DCCR, together with external, natural history studies Soleno intends to...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

Zacks Investment Research - 3 months ago

As of late, it has definitely been a great time to be an investor in Soleno Therapeutics.

GlobeNewsWire - 3 months ago

Updated Results Demonstrate Significant DCCR Exposure Response Relationship

Zacks Investment Research - 5 months ago

Soleno (SLNO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...

Zacks Investment Research - 5 months ago

We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.

Forbes - 6 months ago

If you're wondering how markets are still surging in light of record-breaking coronavirus cases, our deep learning algorithms paired with Artificial Intelligence (“AI”) technology has you cove...

Other stocks mentioned: BHF, EYES, JAGX, RMBL
Forbes - 6 months ago

Being concerned about the elevated levels of the market is likely to be on many investors’ minds ahead of a slew of corporate earnings coming, not to mention an election season that is only go...

Other stocks mentioned: AIRG, BHF, TXMD, VECO
Forbes - 6 months ago

As the Nasdaq continues its historic climb, the Dow has erased some of Monday's gains. The coronavirus will continue to make headlines as its cases grow at a consistent rate across 23 states.

Other stocks mentioned: AIM, ALT, BHF, SGBX
GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., June 26, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel the...

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel ther...

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel the...

Zacks Investment Research - 7 months ago

Soleno (SLNO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Investment Research - 7 months ago

Soleno Therapeutics, Inc. (SLNO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 7 months ago

Study Did Not Meet Statistical Significance for Primary Endpoint, but Showed Significant Improvements in Prespecified Subgroup with Severe Hyperphagia

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Soleno Therapeutics (SLNO) stock based on the movements in the options market lately.

Zacks Investment Research - 11 months ago

Capnia, Inc. (SLNO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Seeking Alpha - 1 year ago

Soleno Therapeutics: A Promising Rare Disease Player For 2020

Zacks Investment Research - 1 year ago

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutic...

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutic...

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

GlobeNewsWire - 1 year ago

Data Published for First Time in Peer-Reviewed Journal Data Published for First Time in Peer-Reviewed Journal

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...

Zacks Investment Research - 1 year ago

Capnia, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Capnia.

Zacks Investment Research - 1 year ago

During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

Zacks Investment Research - 1 year ago

Does Capnia, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Benzinga - 1 year ago

Shares of thinly traded micro-cap biotech Soleno Therapeutics Inc (NASDAQ: SLNO) were surging Friday on over 700 times their average volume.

About SLNO

Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is head... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 13, 2014
CEO
Anish Bhatnagar
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
SLNO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price forecast is 8.67, which is an increase of 310.90% from the latest price.

Price Target
$8.67
(310.90% upside)
Analyst Consensus: Strong Buy